Executive Interview – Richard Barfield, CFO

In this interview, Ergomed’s CFO Richard Barfield runs through:

  • The highlights of Ergomed’s recent trading update, with total H120 revenues increasing by 14.8% to £40.4m.
  • How Ergomed has demonstrated significant resilience through the COVID-19 crisis.
  • Some of the reasons behind the startling growth in Ergomed’s revenues over the last three years and how it intends to maintain that momentum.
  • An overview of Ergomed’s M&A strategy.
  • The outlook towards upcoming newsflow.

Ergomed is a global full-service CRO business with a core focus on the US and EU. It provides Phase I–III clinical services in addition to post-marketing pharmacovigilance (Phase IV) services through its PrimeVigilance division. The company is predominantly focused on oncology, orphan drugs, rare diseases and pharmacovigilance.

 

 

This site uses cookies to personalize and customize your experience. By clicking “I Accept", you consent to cookies in accordance with our privacy policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.


  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services
Secured By miniOrange